Rationale: The Severe Asthma Research Program cohort includes subjects with persistent
asthma who have undergone detailed phenotypic characterization. Previous univariate …

In 1979 and 1980, the chemical structures of the material previously known as slow-reacting
substance of anaphylaxis were elucidated as 5(S)- hydroxy- 6(R)-glutathionyl- 7,9-trans-11,…

Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The …

BACKGROUND: Severe asthma causes the majority of asthma morbidity. Understanding
mechanisms that contribute to the development of severe disease is important. OBJECTIVE: …

Rationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure in which controlled
thermal energy is applied to the airway wall to decrease smooth muscle. Objectives: To …

Background Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are
effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new …

Background The issue of whether regular use of an inhaled β 2 -adrenergic agonist worsens
airflow and clinical outcomes in asthma is controversial. Retrospective studies have …

Background: A clinical model is needed to compare inhaled corticosteroids (ICSs) with
respect to efficacy. Objective: The purpose of this investigation was to compare the relative …

Background Long-acting beta-agonist (LABA) therapy improves symptoms in patients whose
asthma is poorly controlled by an inhaled glucocorticoid alone. Alternative treatments for …

Clinically similar asthma patients may develop airway obstruction by different mechanisms 1,
2. Asthma treatments that specifically interfere with the 5-lipoxygenase (ALOX5) pathway 3, …